With a market capitalization (market cap) of $2.05B — a measure of how much the company is worth — Agios Pharmaceuticals, Inc. is the 2094th most valuable company in Healthcare as of August 18, 2026. Shares trade at $34.40, up +2.29% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Visit websiteAs of August 18, 2026, Agios Pharmaceuticals, Inc. (AGIO) is worth $2.05B — this is its market capitalization, the total value of all its outstanding shares.
Agios Pharmaceuticals, Inc.’s market cap is $2.05B, which ranks it #2094 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Agios Pharmaceuticals, Inc. (AGIO) shares trade at $34.40, up 2.29% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025